Mettler-Toledo International Inc (MTD) 2008 Q2 法說會逐字稿

Good day, ladies and gentlemen, and welcome to our second quarter 2008 Mettler-Toledo International earnings conference call.

My name is Cara, and I will be your audio coordinator for today. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. (OPERATOR INSTRUCTIONS)

I would now like to turn our presentation over to your hostess for today's call. Ms. Mary Finnegan, please proceed, ma'am.

Thanks, Cara, and good day, everyone.

I'm Mary Finnegan Treasurer and responsible for Investor Relations at Mettler-Toledo and I'm happy to welcome you to the call. I'm joined by Robert Spoerry, Olivier Filliol, and Bill Donnelly. I'll start by covering some administrative matters, and then turn the call over to Robert.

Now for the administrative matters. First, this call is being webcast and is available for replay on our website at www.MT.com. A copy of the press release we issued today is also available on our website. You should be aware that statements on this call which are not historical facts may be considered forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995.

Forward-looking statements involve risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied. For further information concerning issues that could materially affect performance related to forward-looking statements, please refer to our filings with the SEC. We undertake no responsibility to release any revisions to forward-looking statements as a result of subsequent events or development.

One other item, on today's call we may use non-GAAP financial measures. More detailed information with respect to the use of and the differences between the non-GAAP financial measure and the most directly comparable GAAP measure is provided in the press release.

I will now turn the call to Robert.

Thank you, Mary, and good afternoon and welcome everybody to the call.

We just finished our board meeting here in Germany in Hanover, and now as the day's end over here, we are very pleased to announce a great quarter. As usual I make some introductory remarks and then Bill will provide details of our financial results and also new guidance. Olivier will then make some additional comments from our growth strategies, but we'll keep our prepared remarks brief as most of you have heard either directly or indirectly an update on our strategic initiatives from our most recent investor meeting. As always, we will have time for Q & A at the end.

I will begin with highlights of the quarter. We have seen continued solid momentum in our business. Local currency sales growth of 11% was very strong and exceeded our expectations. We had good growth across the board. Most geographic regions and product lines contributed to these very nice results.

These strong sales growths led to an 18% increase in operating profit and a very strong 28% increase in our [trusted] EPS. Growth in cash flow was also good with cash flow per share up 26% in the quarter. With these results we are again increasing our guidance for the full year. Momentum in our business remains solid, but we are also alert for potential slow down. Bill has further comments on guidance and our outlook later on the call.

I will now turn the call over to Bill for more details on the financials. Please, Bill.

Thanks, Robert, and hello, everybody.

As you heard from Robert we had a good quarter and are very pleased with the results. Let me begin with adjusted earnings per share which came in at $1.40, a 28% increase over the prior year amount of $1.09. For the quarter adjusted EPS excludes purchased intangible amortization expense. On the last page of our press release, we have a table that details the calculation of adjusted EPS.

Let me provide you with more details beginning with sales which were $515.6 million in the quarter, an increase of 11% organically in local currency. On a U.S. dollar basis, sales increased by 20% in the quarter which included a 9% currency benefit. I know I have said this before but given the strong impact of currency in our results, I want to highlight the impact of our currency.

Although we do have a cosmetic benefit to the topline due to the weaker dollar, it is local currency sales growth that drives our operating profit growth. This is because we're relatively naturally hedged with our non-dollar sales approximating on our non-dollar costs. The net impact of currency on operating profit and earnings per share tends to be relatively small.

Breaking down sales by geographic destination, and all these percentages are in local currency, we are very pleased with the 10% local currency growth we reached in Europe. We had good growth in the quarter in almost all product lines. For the first six months of the year, sales are up by 7% in Europe. Sales growth in the Americas increased by 7% on an organic basis. We had very good growth in lab and in food retailing.

Industrial was up as well with strong growth in product inspection, offset by a reduction in one of our OEM customers. Year-to-date sales are up 4% on an organic basis in the Americas. Sales in Asia/rest of the world increased by 22% in the quarter with all product lines showing very good growth. Year-to-date our sales in Asia/rest of the world are up by 20%.

Now, turning around and looking at it by product area, we had 11% organic growth in laboratory with good growth in almost all product lines. For the first six months, laboratory sales are up by 10% on an organic basis. Industrial sales also grew by 10% in the quarter with strong growth in both core industrial products and the product inspection side; and for the first six months, industrial sales were up by 8%.

Finally, retail was up by 16% in the quarter with good growth both in Europe and in the U.S. Year-to-date sales are up by 3% in retail. I've kept my remarks here brief as Olivier will provide additional insight on sales by product category.

Now let's look at gross profit margins. They increased by 20 basis points in the quarter to 50.2%. We drove 150 basis point margin expansion in the quarter on a constant currency basis. There were few items that came together to give us this strong result. This includes the impact of price increases in excess of our material cost increases as well as the impact of leverage. Mix was relatively neutral in the quarter. Currencies did decrease gross margins by about 130 basis points. This goes back to the impact of the weaker dollar which I described before.

Let me make some additional comments on raw material prices, as I know it is an area of focus for many of you. Steel is an important raw material category for us as we use it in most product lines but especially in our industrial products. We continue to be successful in limiting the impact of cost increases through procurement initiatives. These initiatives include using more low cost country suppliers and further consolidating the supply base. Our material price index, which is how we track year-over-year material cost inflation, is up about 50 basis points this year.

We are also making supplemental price increases over and above our normal increases in those product areas where product lines are particularly impacted by steel prices.

In summary, we are more than off setting our material inflation as evidenced by our strong margin expansion.

R&D amounted to $26.7 million or 5.2% of sales, a 7% increase in local currency; while SG&A was $157.1 million, an increase of 11% in local currency. Let me break this down a bit more. Of course with the top line growth of 11% we have higher sales, commissions and associated sales related expenses. Our incentive compensation also increased during the period because of the strong performance. Beyond that, we also had increased investments in sales and marketing, especially in emerging markets. The net sum of all these P&L items is the result--results in a strong operating income.

Adjusted operating income increased by 18% to $75.2 million as compared to $63.8 million a year ago. On a constant currency basis, our operating margins grew by 100 basis points in the quarter. Now continuing down the rest of the P&L. Amortization amounted to $2.7 million in the quarter while interest expense was $6 million. Other expense amounted to a $0.5 million. Our tax rate was 26% and we expect it to remain at that level.

Now for the share repurchase plan. During the quarter we repurchased 585,400 shares for a total amount of $58.3 million. Fully diluted shares for the quarter were $35.3 million and at the end of the quarter we are at 35 million shares even. Our share count is currently 8% lower than at this time last year.

Finally, earnings per share on a reported basis was $1.38 in the quarter. This compares to $1.07 in the prior year. Adjusted earnings per share were $1.40 which is a 28% increase over the prior year amount of $1.09. For the first six months adjusted earnings per share was $2.41, a 28% increase over the prior year amount of $1.88.

Now let me turn and take you through cash flow. Free cash flow for the quarter was $64.4 million as compared to $55.3 million a year ago. This results in free cash flow per share of $1.82 which is a 26% increase over the prior year amount of $1.44. We are obviously very pleased with this growth.

Our DSO was at 44 days in the quarter, a two day improvement over a year ago. And as I said on previous occasions, we are really pleased with the absolute level of DSO. ITO came in slightly lower than last year. That covers the quarter, but let me now take you through our guidance.

As you see with our Q2 results, momentum remains very solid in our business. At the same time we continue to be alert for any potential slow-downs in the global economy. We want to be positioned to react quickly if it is necessary. Now, let me give you some additional color for the rest of the year.

Let's start with Q3. We would expect local currency organic sales growth for the quarter to be in the range of 6% to 8%. This is higher than we had previously communicated to you. We are starting the quarter with a very solid backlog and haven't seen slow down in our markets to date. This sales growth should translate into an adjusted earnings per share growth of $1.33 to $1.35, an increase of 16% to 17%.

For the full year we would expect adjusted earning per share to be in the range of $5.53 to $5.63 per share, which represents a growth of 17% to 19% over 2007. This compares to our previous guidance which had assumed a growth rate of 15% to 17%. For clarification purposes, I just want to remind you that adjusted EPS excludes the $0.07 expense related to purchased intangible amortization and a $0.07 per share gain for the discrete item--tax item that we had in the first quarter.

One piece of background information I want to share is that we've assumed a refinancing of our existing debt in Q3. We have decided to refinance now as we were approaching a full utilization of our credit facility. The combination of the new facility as well as some longer term financing will provide higher interest costs in the short-term but we've already built this into the guidance we just provided you.

Okay, that's it for my side and I will turn it over to Olivier who will provide some commentary on the quarter.

Thank you, Bill, and hello, everyone.

I will start with some commentary on the results and then turn to our growth strategies. As you have just heard from Bill, we had a great second quarter which is on top of a solid first quarter positions us well for this year. We feel confident in the year ahead, which is reflected in the increased guidance Bill has just outlined to you. We are of course cautious on the economy and will continue to monitor it closely.

Now let me provide some additional comments on the quarter. We had a very strong quarter with organic sales up 11%. Similar to what we saw in the first quarter, the sales growth level was broad based across most product lines and geographies. We continue to benefit from our strong product pipeline, our [Spinac] initiative surrounding sales and marketing and strong growth in emerging markets.

Turning to industrial. Our core industrial business was strong in the quarter with very strong growth in Asia and good growth in Europe. Growth in Americas was down slightly but I would note that this against strong growth in prior year. Product inspection had another quarter of strong sales growth as market conditions in this business continue to be favorable. Finally, retail was up 16% with good growth in Europe and the Americas. We had nice productivity in both regions. That's all I wanted to comment on for the business.

Now let me make just some brief comments on our growth strategies. Many factors are contributing to our operating results including strong results in emerging markets, continued leverage of Spinac related programs and our focus on technology leadership. Let me cover this last topic in some more detail as it is an important driver of our sales growth.

Our product innovation continues to focus on solutions with tangible paybacks to customers. I would like to illustrate this with an example from process analytics where we have introduced new technology to help our customers improve yield and lower maintenance costs.

As a reminder, our processor (inaudible - highly accented language) business provides process industries such as pharma, biotech and chemical companies solutions for monitoring and optimizing liquid production processes. Our solution is to combine sensor technologies with transmitters to measure various analytical parameters. We integrate our solution with plant wide control systems and provide continuous monitoring of analytical parameters like pH, dissolved oxygen and [TOC]. In line measurement has many advantages versus taking a sample in a QC lab for analysis.

One final note on the business before I explain our new solution. It is absolutely critical that these in line sensors are properly calibrated, maintained, and replaced on a timely basis. The malfunction or failure can have significant impact on the quality of product being manufactured and can have tremendous impact on yields.

Let me explain. A production batch for a pharmaceutical company can be in the range of $5 million to $10 million. If the sensor fails during production, the entire batch is lost. This is a huge cost to customers. Now let me explain our new solution. It consists of three elements, digital analytical sensors, new advanced transmitters and an asset management software tool. We are marketing this unique solution under the name ISM which stands for Intelligent Sensor Management.

Let's start with the sensor. It has fully integrated electronics including intelligence referred to above. The intelligence is in productive diagnostics capabilities that manage the sensor through its lifecycle. This life cycle includes the needs for maintenance, calibration and eventually replacement, which I described earlier. And each of the stages of lifecycle are revenue opportunity for Mettler-Toledo.

The transmitter takes the information from the sensor and measures, displays, and transmits it to the process control system. Our new transmitter has been designed to allow for a high degree of flexibility in its interface. Specifically it can control a variety of sensors and we expect to add more parameters in the future. The transmitter also allows the customer to integrate the diagnostics data into its process control system and get real time alarms to avoid unexpected downtime and thus optimize yield.

The final aspect of our solution is the asset management software tool which manages the installed base in terms of calibration and replacement. Calibration at the facility can be done centrally and is safe, easy and more accurate than when performed in the field. In terms of managing the replacement, the sensor provides a unique dynamic indicator which the software uses to continuously estimate the remaining useful life by considering irrelevant viables such as temperature levels, resistance levels and [others]. This avoids unexpected downtime and also maximizes the life of a sensor.

The software tool also allows the customer to manage his entire installed base sensors and document all changes which is important for many industries including the pharmaceutical industries. Our new solution provides a significant and tangible pay back to customers based on lower maintenance costs and higher yield in production typically in the range of six months. And as might be expected with such a powerful tool, initial customer reception is very favorable. This is just one example of a product launch that I thought it was a good illustration of a comprehensive solution that provides tangible payback to our customers.

That is all that I wanted to cover today. In summary, we are very pleased with the strong operating results in the quarter. We have again raised our guidance for 2008 and remain confident in our ability to execute our initiatives. Momentum in our business remains solid. We remain cautious on the economy and will continue to monitor it closely. We are ready to adjust our expense growth should conditions weaken.

With that, we conclude our prepared remarks and I would now like to ask the operator to open the line for questions.

(OPERATOR INSTRUCTIONS) Your first question comes from the line of Jon Wood with Banc of America Securities .

Thanks a lot.

Robert or Olivier, can you give us an update on the Quantos launch, will that product be material in the back half of the year or will it take longer to make a meaningful contribution?

Actually, important to note we have introduced Quantos into the market but in terms of shipping the machines, the instruments we will want to start to do that in Q4. And it will ramp up gradually. So in Q4 it will have an impact but the major impact is really starting next year then.

Okay, and then on the retail, the new retail solutions, is that primarily responsible for the strength in that unit?

Partially but actually we had broad based growth, the main concern in Europe. And yes, we have some major projects coming in that are driven by the different innovative solutions that we have also presented at the most recent investor meeting. But I wouldn't say it is just that.

Okay, and then, Bill, I understand your comments on the purchasing index, has anything changed since last quarter?

In terms of material prices?

I think on a year-to-date basis we did see second quarter on a year-to-date basis is a little bit ahead of where we were in the first quarter, so we saw some slowing down; but that could as much be as anything the mix within the quarter. So I wouldn't jump too much that we see necessarily a flattening out. I did see some things on the steel futures and stuff. Maybe that will improve somewhat down the road. But we're just [going to] continue to work hard on little things to try to manage that cost.

So there has been no incremental price increases planned since your last call?

I'm sorry I misunderstood you. I thought you were asking more about our supplier costs.

Yes, I was, and then--I'm sorry, I was, I flipped around.

On the sales prices we are raising prices, we actually did relatively aggressive mid-year prices, increases, raising prices. That is more than we have in prior years and in particular on these products that have significant steel content.

Okay, thanks and then Robert or Olivier can you just comment on the M&A pipeline, have you been more active on that front or asset prices still a bit unreasonable? Thanks.

Actually, our view on M&A is still the same in the sense that we feel very strong about our franchise and we feel that they have great opportunities for us to further optimize.

We are open to M&A particular in the area of life science like lab process analytics. But in the very short-term, we don't have something that we just see now materializing. But I feel good about the platforms that we have and, yes, we all are looking for different opportunities that down the road might materialize.

Okay, thanks a lot.

Your next question comes from the line of Peter McDonald with Wall Street Access.

Could you talk a little bit about how service did in the quarter?

Sure, service grew mid-single digits in the quarter, I think it was 5%, a little less than the product side of the business and profit growth was good in that part of the business as well.

Okay, and then how much is -- do you have remaining on the stock repurchase plan?

We have nearly $0.5 billion and--but just as a reminder, that originally started out as a couple hundred million dollar plan and the board has approved it periodically and I think if we got down to a relatively low level we would -- assuming our balance sheet and other outlooks were the same would go back for more.

And just touching on the process analytical in line measurement product area, who is the key customer base that you will be targeting that with? Is it a retrofit type of a sale or is it for new plants or across the board?

It is across the board but we actually see that existing plants are regularly updating their measurement loops and so there is actually a lot of retrofit opportunities.

When we talk about the end user industries, it is very strong actually in the biotech pharma area. That is the main target industry segments, but we actually see that the chemical industry, petrochem industry, is also very, very interested in this concept. These are our two most industries that are most targeted.

I think that's it. Actually, just to--going back, have you passed on incremental price increases since the beginning of the year just to reflect?

Yes, we did.

Thanks a lot and congratulations on a good quarter.

Thank you.

Your next question comes from Tycho Peterson with JPMorgan.

[Gigi] sitting in for Tycho today. First question is could you comment on the competitive landscape in China particularly coming from the low cost manufacturers and if you're seeing any material impact there?

They are around, no question about that. We don't face them in all of our market segments. I think we need to differentiate here. When we talk about the laboratory balances, when we talk about titration, and PA, we see them very less especially in industrial and retail business, they are non-existent.

The way we look at the Chinese market is kind of a three tier. There is this high end mid tier where it is more mainly import brands and where we are extremely well positioned and then for the low tier, very competitive tier there, we see the local competitors and we want to actually get stronger in it. That's also one of the reasons we are actually innovating to with local products. But in terms of market size today, it is not so huge the segments and the competitors are all very small. It is a very fragmented competitive landscape.

For your--I guess your outlook for food retailing segment, has that improved since the last quarter given the stronger performance this quarter for the remainder of the year or--?

Are you asking that in Q1 our growth in retail wasn't as strong but this was against a very difficult previous year comparison. The comparison for the rest of the year should actually not be as difficult. In that sense, we are looking for good outlooks in the retail business for the rest of the year.

Great. Thank you very much.

Your next question comes from the line of Rob Mason with Robert W. Baird.

Nice job, guys. Bill, real quick, do you have the sales by the three main product lines; lab, industrial, retail?

Sure. In the quarter, it was 43% lab, 44% industrial, and 13% retail.

Okay. Do you have any sense that your customer's order patterns were influenced in the quarter or your shipments may have been influenced either by the Easter movement or by your price increases late--I guess early 3Q but might have--they have been pulling some demand forward?

On the price increases I definitely don't think--we pretty much didn't announce them until it would have been too late in the quarter. With regard to working days, I think we would tend to look at on a year-to-date basis, I think that has worked itself out. We certainly lost a couple working days in Q1, gained a little bit here. I think if you look at kind of our year-to-date results, you get a pretty good feel.

Okay, and then maybe just last thought, as you have moved through the quarter, the macro indicators really degraded in Europe and I'm just curious if you--it's not obvious from your second quarter results but as you enter the third quarter if you are seeing maybe evidence of those indicators turning down so significantly in June?

We don't see it in our business and we don't--any tentative early indicators that we have don't show it, but of course we remain alert. We also listen to what the other industrial companies are [serving] and so on and we take it very serious, but we don't have yet any early signs of a slow down.

So your order intake has been good into July?

Yes, and that's really also why we have a solid outlook for Q3. We are really confident about that.

Very good. Thank you.

Your next question comes from the line of Peter Lawson with Thomas Weisel Partners.

It is actually Patrick Donnelly in for Peter.

Bill, I appreciate the color you gave on steel, but I was just wondering how much of the price increase are you actually able to pass on to customers and are you seeing any push back from customers on that?

Of course, there are customers that push back, but we feel that we have been able to push price increases through on a majority of our product lines to the majority of the customer base. Even places like China we are pushing up price increases which maybe historically has been one of the more difficult markets. And I think it is evidenced in the margin expansion year-to-date if you look at--it is not really mix related. It is very much prices in excess of the material costs going up. So that is a good sign.

So we feel pretty confident about how that will go in the second half of the year with what we are doing mid-year.

Okay, and I know there is a lot of focus on Asia, especially the Analysts' Day, you guys focused a lot on it. Would you mind giving us some color on some of the other emerging economies, like Russia and India, what you are doing there?

Actually both countries are important to us and have good momentum. We also continue to invest actually in Russia like in India in significant ways. And they are actually growing for us in a similar way as China and in that sense very important contributions. We also in both Russia and India, we are represented across all the product lines, business lines.

Great. Congratulations on the quarter, guys.

Thank you.

(OPERATOR INSTRUCTIONS) Your question comes from the line of Jason Rodgers with Great Lakes Review.

Hello. Wondering if you could give the sales breakdown as a percentage of sales for service and consumables in the quarter?

Service and consumables together are probably about 33% or so in the quarter.

Okay. Do you have the separate break out of those?

Roughly 23% coming from--22, 23% coming from service and the rest coming from the consumable side.

Okay and inventories were up about 25% or so from the prior year, a little bit higher than the sales increase. Just wondered if there was anything behind that?

Inventory. Yes, sorry, I didn't catch the beginning. We have currency impacts on inventory is one element. So if you did it on a constant currency basis, we've had kind of a seasonal increase but not so much larger than a seasonal increase.

One thing that we are doing is we are moving more and more of our transportation from air to sea. That linked in some of the--puts more inventory in transit for us. As an example some of the lab balances we ship into Fisher, we are now doing by sea. Then, second example is that we continue to move more and more production to China. And just generally speaking of course it is more cost effective overall but it does mean for some longer lead times.

And finally, have you seen any change in demand trends from your pharmaceutical customers in the lab business?

I don't think particularly in this quarter--that wouldn't be the case. I think the fire market has been okay but not particularly exciting.

Okay. Thank you.

(OPERATOR INSTRUCTIONS) It appears that there are no further questions. I would now like to turn call back to management for any further comments or closing remarks. And it looks as if we do have follow-up from the line of Jon Wood with Banc of America Securities.

Thanks. Bill, is the new product vitality changed at all? I'm just trying to figure out, it looks like your numbers are going in the exact opposite direction of logic and across the board. Has there been any change in new products as a percent of sales over either sequentially or year-over-year?

I would say in total, no. We certainly have seen the power of what we have done in terms of lab balance portfolio and some other things, but overall, it's not moved materially.

Okay, any other comments on--has there been even a change at the margin at the competitive landscape level, particularly industrial?

Not really.

Not really.

Okay. Thank you.

We are just trying to execute well, Jon.

It looks pretty good.

Thank you. Operator, are there any more questions.

You do have another question from the line of Jonathan Groberg with Merrill Lynch.

Thanks for taking my call, sneaking in here, as you know there are a number of calls going on. But congratulations on a very fine quarter.

Probably some of these questions have been asked. So my only question--what I have seen from a number of good executing companies recently is they put up some pretty stellar numbers in this quarter in terms of organic revenue growth. And I'm just wondering, you have I think kind of a reputation for being a late cycle company and is all of this kind of hitting right before the economy slows. I was wondering if you can maybe touch on that or talk about that.

I guess with regard to the comment of late cycle that there is some elements of that but of course there are other parts of our business that I would say are less so in that category. And maybe what I would also say is that as compared to maybe any earlier downturns, the mix of our business has changed just to give a couple of examples, service and consumables as a percentage of sales have grown nicely.

We have a lot of things going in that will make that continue to be solid growth and then of course emerging markets as a percentage of sales as well. So I think we said it several times on the conference call that at this point we see no reason that--we see no slow down in terms of momentum but hey, we read the paper, we stay alert and we want to be well position to act on our cost structure if it needs to be.

Okay. But from the--that was a difficult question to answer but I'm just wondering are you guys cognizant obviously and how quickly do you think you could respond should things change fairly dramatically in terms of pulling the right levers to keep things in check from a cost perspective?

We covered that at the last conference call that we had actually initiated at the end of the Q1 contingency plans within the organization. We partly executed on them and the other part we have basically ready if things would turn in the wrong way. In that sense we feel prepared to react actually quite fast on it.

Okay, great. And then if you have talked about this, let me know and we can talk offline or I can read it. But at your Analyst Day, which was excellent again, you talked about a number of new products that you had introduced and maybe you can just give an update as to how some of those are playing out in the field.

I think one of the major one that we presented there was Quantos. And Quantos, just to remind, is a product that we launch it in the market but we will ship it in Q4 and we are rolling it out globally on a gradual basis.

We had, however, a lot of customer demonstrations and testing installations. Receptions have been very, very strong and in that sense we are very confident that we will meet our forecast on this product.

The other products that we had on retail that gets good receptions in the market, this is something that we are presenting to customers in all major projects, opportunities and we feel actually also very good about that too.

Great. Congratulations.

You do have one final question in the queue and it comes from Charles Yuen with Neuberger Berman.

Hello, Charles.

Sorry, can you hear me now? Great quarter. Have you seen an acceleration in the share gains versus competition through the first half of the year?

Different by product line. I--we clearly think that there is some market share gain. We don't think the market is growing this quickly, but I can't necessarily point in particular to any one competitor that we are gaining more than another.

I think--I wouldn't say just the last two quarters. Normally, we succeed to grow about 1.5 to 2 times the market growth and so we feel that we are gaining market share continuously over the last few quarters, not just the last two quarters.

Okay. Thanks. Great quarter.

Sure.

That was your final question in the queue. Do you have any further comments or any closing remarks?

Thank you all for joining us and we look forward to talking to you next quarter. Thank you.

That concludes this evening's teleconference. You may now disconnect.